Research Topics
| Richard PensonSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Between parent and child: negotiating cancer treatment in adolescentsRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 7:154-62. 2002..The epidemiology of cancer in adolescents and paradigms of care are reviewed. Psychosocial aspects of adolescence, opportunities for personal growth and support, and the challenge of end-of-life care are discussed...
Fear of deathRichard T Penson
Department of Medicine, Division of Hematology Oncology, Palliative Care Service, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 10:160-9. 2005..Through an examination of eight caregiver narratives of their patients' experiences, the role of the health care provider in the dying process, particularly in regard to challenging fear, is reviewed...
Laughter: the best medicine?Richard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, 02114 2617, USA
Oncologist 10:651-60. 2005..Through an examination of physician and nurse experiences, the role of humor in medicine is reviewed...
Topotecan: weighing in when there are many optionsRichard T Penson
Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Oncologist 10:698-700. 2005....
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumorsR T Penson
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Int J Gynecol Cancer 15:1035-41. 2005..The optimal dose and schedule of gemcitabine is yet to be defined in this population...
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumorsRichard T Penson
MRCP, Division of Hematology Oncology, Yawkey 9 064, Massachusetts General Hospital, 32 Fruit St, Boston MA 02114, USA
J Clin Oncol 28:154-9. 2010..The progression-free survival rate at 36 months was 58%. CONCLUSION The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer...
The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homelessRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
Oncologist 8:488-95. 2003..The team developed a strong commitment to his care and an affectionate bond, which very positively affected all of those involved. We discuss issues of access to cancer care, and the special problems presented by homeless patients...
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignanciesRichard T Penson
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
Gynecol Oncol 93:702-7. 2004..Topotecan and pegylated liposomal doxorubicin (Doxil) interact with topoisomerase I and II (topo I and II), respectively, with schedule dependent, and potentially synergistic cytotoxicity...
Help me help you: support groups in cancer therapyRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 9:217-25. 2004..The article discusses issues of support and the role of formal support groups. Types of support intervention, the impact they have on quality of life and survival are reviewed...
Too old to care?Richard T Penson
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 9:343-52. 2004..Discussion in the Rounds focused on age bias, drug toxicity, life prolongation, and symptom relief, with the role of the caregiver, and the relationship to the patient, being pivotal...
Attitudes to chemotherapy in patients with ovarian cancerR T Penson
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
Gynecol Oncol 94:427-35. 2004..Recurrent ovarian cancer (OVCA) has become the model for cancer as a chronic disease, yet little is known about what motivates patients and physicians in treatment choices...
Cancer as metaphorRichard T Penson
Department of Medicine, Hematology Oncology, Cox 548, 100 Blossom Street, Boston, Massachusetts 02114 2617, USA
Oncologist 9:708-16. 2004..The advantages and disadvantages of the use of this metaphor are discussed, as well as the use of other metaphors in the psychosocial dynamic of care...
HopeRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Yawkey 9066, 55 Fruit Street, Boston, Massachusetts 02114 2617, USA
Oncologist 12:1105-13. 2007..The literature and limited evidence base are reviewed...
Bevacizumab and ovarian cancerG G Y Lai
Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Drugs Today (Barc) 47:669-81. 2011....
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
Br J Cancer 93:54-9. 2005..Oral etoposide 35 mg m(-2) b.i.d. D1-5 and 1.8 mg m(-2) 96 h (total dose) infusional topotecan D8-11 can be administered on an alternating continual weekly schedule for at least 12 weeks, with promising clinical activity...
Quality of life in ovarian cancerRichard Penson
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
J Reprod Med 50:407-16. 2005..While the humanities perhaps teach us much about the value of QOL, the science of the study of QOL will be the foundation and confirmation of many of the anticipated advances for patients...
Teams: communication in multidisciplinary careRichard T Penson
The Kenneth B Schwartz Center at Massachusetts General Hospital, Department of Medicine, Boston, Massachusetts 02114 2617, USA
Oncologist 11:520-6. 2006..This article explores the tough issue of how teams handle uncertainty and bad news and how patients and families can be better supported in the multifaceted paradigm of modern care...
Trust violated: analgesics for addictsRichard T Penson
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
Oncologist 8:199-209. 2003..With open and honest support, the team was able to both care for and empower the patient. Issues of trust, liability, opioid tolerance, and barriers to optimal analgesia for cancer pain are discussed...
Medical mistakes: a workshop on personal perspectivesR T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 6:92-9. 2001..Openly sharing experiences in a confidential setting, such as the Schwartz Rounds, helps defuse feelings of guilt and challenges the culture of shame and isolation that often surrounds medical errors. The Oncologist 2001;6:92-99..
Randomized placebo-controlled trial of the activity of the morphine glucuronidesR T Penson
Department of Medical Oncology, St Bartholomew s Hospital, London, England
Clin Pharmacol Ther 68:667-76. 2000..It has been suggested from animal model data and by examination of metabolite ratios in humans that M3G may functionally antagonize the respiratory depressant and analgesic actions of morphine and M6G...
Caring for colleaguesR T Penson
Department of Medicine, Division of Hematology Oncology, Cox 809, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114 2617, USA
Oncologist 6:197-204. 2001....
Losing GodR T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114 2617, USA
Oncologist 6:286-97. 2001..Simply being there for the patient and being open to their hurt can help resolve their spiritual crisis, a responsibility that is shared by the whole health care team...
Complementary, alternative, integrative, or unconventional medicine?R T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 6:463-73. 2001..Concern about drug interactions and adverse effects are compounded by a lack of Food and Drug Administration regulation. Physicians need to be informed about CAM and be attuned to the psychosocial needs of patients...
Limited phase I study of morphine-3-glucuronideR T Penson
Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114, USA
J Pharm Sci 90:1810-6. 2001..1 (+/- 4.8) liters. At the doses investigated there were no clear neuroexcitatory effects, no opioid effects, and the pharmacokinetics were very similar to those of morphine-6-glucuronide (M6G)...
Sexuality and cancer: conversation comfort zoneR T Penson
The Kenneth B Schwartz Center at Massachusetts General Hospital, Hematology Oncology Department, Boston, Massachusettts 02114 2617, USA
Oncologist 5:336-44. 2000..A sensitive and informed approach to discussing sexuality can provide effective support. The elements of successful dialogue are presented in the PLISSIT model...
Communicating genetic risk: pros, cons, and counselR T Penson
Hematology Oncology Department, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 5:152-61. 2000....
Burnout: caring for the caregiversR T Penson
The Kenneth B Schwartz Center at Massachusetts General Hospital, Hematology Oncology Department, Boston, Massachusetts, USA
Oncologist 5:425-34. 2000..They considered preventative measures including psychological support of the health care team, communication and management skills, and effective coping mechanisms...
Virtual connections: Internet health careRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Cox 548, 100 Blossom Street, Boston, MA 02114 2617, USA
Oncologist 7:555-68. 2002....
Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer CenterRichard T Penson
M R C P, Hematology Oncology, Yawkey 9064, 55 Fruit Street, Boston, Massachusetts 02114, USA
Oncologist 15:760-4. 2010..In this article we explore the reasons that contribute to the success of this model of multidisciplinary reflection...
When does the responsibility of our care end: bereavementRichard T Penson
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 7:251-8. 2002..A compassionate response helps both those who suffer and those who care. Complicated and uncomplicated bereavement, grief reactions, resources for bereavement counseling, and the role of condolence letters are reviewed...
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancerUrsula A Matulonis
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Pain Symptom Manage 30:563-9. 2005..No significant toxicities were attributable to octreotide or LAR. Because three patients received nine or more monthly injections of LAR, possible direct antitumor effects of LAR or synergy with chemotherapy needs to be explored...
Living as a cancer surpriser: a doctor tells his storyKristine A Knuti
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 8:108-22. 2003..In addition to such processes, patient-caregivers with cancer also find that their own medical knowledge and their colleagues' reactions shape their experiences and to an extent separate them from those of other patients...
Phase II trial of anastrozole in women with asymptomatic müllerian cancerMarcela G del Carmen
Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
Gynecol Oncol 91:596-602. 2003..A minority of patients demonstrated prolonged stable disease while on this agent...
Direct-to-consumer advertising in oncologyGregory A Abel
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114-2617, USA
Oncologist 11:217-26. 2006..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed...
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumorsUrsula A Matulonis
Department of Medical Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
Gynecol Oncol 112:394-9. 2009..The primary objective was to determine the completion rate of 6 cycles of paclitaxel and carboplatin chemotherapy with no dose reductions in patients > or =70 years of age...
Learning to cope: how far is too close?Brian M Wolpin
Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 10:449-56. 2005..To conclude, further educational initiatives are advocated to assist both physicians-in-training and more senior clinicians in dealing with the difficult issues that arise when caring for very ill and dying patients...
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerUrsula A Matulonis
Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
J Clin Oncol 27:5601-6. 2009..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit...
Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovaryLinda R Duska
Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Gynecol Oncol 85:459-63. 2002..The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy...
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancerUrsula A Matulonis
Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston MA 02115, USA
J Clin Oncol 26:5761-6. 2008..Pemetrexed is a multitargeted antifolate with manageable toxicity and has been combined with carboplatin to treat other cancers...
Breaking bad news: a patient's perspectiveLauren Dias
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 8:587-96. 2003..This article discusses issues of support, abandonment, and how hope is conveyed, and reviews the literature that informs good clinical practice in breaking bad news...
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitorEmily S Robinson
Channing Laboratory, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115, USA
Clin J Am Soc Nephrol 5:477-83. 2010..In this phase II study of cediranib (AZD2171) for recurrent epithelial ovarian cancer, the time course and severity of BP changes and proteinuria were characterized...
Psychosocial issues in adolescents with cancerAnnah N Abrams
Department of Child Psychiatry and Pediatric Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, United States
Cancer Treat Rev 33:622-30. 2007....
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and managementPaul E Hesterberg
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA
J Allergy Clin Immunol 123:1262-7.e1. 2009..Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs). How best to risk-stratify patients for desensitization is uncertain...
Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological CancerRichard T Penson
Harvard Medical School, Boston, MA, USA
Int J Gynaecol Obstet 95:S247-57. 2006..The QOL issues facing gynecologic cancer patients, the use of validated QOL instruments, recent advances in the evaluation of interventions, and changes in concepts related to QOL are reviewed...
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancerMichael V Seiden
Gynecologic Oncology Research Program at Dana Farber Partners Cancer Care Program, Boston, MA 02115, USA
Gynecol Oncol 101:55-61. 2006..To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy...
Comparison of the quality of life of early and advanced stage ovarian cancer survivorsKristina L Mirabeau-Beale
Harvard Medical School, Boston, MA, USA
Gynecol Oncol 114:353-9. 2009..The objective of this study was to compare the long-term adjustment and QOL of early and advanced stage ovarian cancer survivors (OCS)...
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumorsSusanna M Campos
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Gynecol Oncol 90:610-8. 2003..The concurrent delivery of the weekly paclitaxel with liposomal doxorubicin may increase liposomal doxorubicin skin toxicity. Liposomal doxorubicin does not alter the pharmacokinetics of paclitaxel...
beta tubulin mutations are rare in human ovarian carcinomaDiana E Lamendola
Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Anticancer Res 23:681-6. 2003..CONCLUSION: This result suggests that mutations within exon four of human beta tubulin are rare in newly-diagnosed and recurrent paclitaxel resistant human ovarian cancer...
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra
Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 25:5180-6. 2007....
Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patientsElizabeth Dean-Clower
Leonard P Zakim Center for Integrative Therapies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Integr Cancer Ther 9:158-67. 2010..The main study objectives were to determine the feasibility of administering acupuncture as palliative therapy to patients with advanced ovarian or breast cancer and to assess the effect on symptoms and quality of life (QOL)...
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerAnna Berkenblit
Dana-Farber/Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Gynecol Oncol 95:624-31. 2004..A starting docetaxel dose of 30 mg/m(2) would be reasonable for future studies exploring the utility of weekly dosing in less heavily pre-treated patients...
Morphine analgesia in cancer pain: role of the glucuronidesRichard T Penson
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
J Opioid Manag 1:83-90. 2005..01) than morphine (r = 0.197, p = 0.05). These data suggest that M6G contributes significantly to the analgesic potency of oral morphine. No evidence was found for differences in M3G. M6G ratios contributing to analgesia or toxicity...
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche
Dana Farber Harvard Cancer Center, representing members of the DF HCC Gynecologic Oncology Research Group at Massachusetts General Hospital, and Dana Farber Cancer Institute, Boston, MA, USA
Gynecol Oncol 116:168-72. 2010..The primary objective was to define the median time to treatment termination (TTT) with women with relapsed ovarian cancer treated with single agent GM-CSF delivered subcutaneously (SC)...
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell linesZhenfeng Duan
Department of Hematology/Oncology Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Cancer Res 9:2778-85. 2003..These antigens, because of limited expression in normal tissues, may be suitable targets for immunotherapy and novel therapeutic strategies in the treatment of chemotherapy-resistant epithelial tumors...
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samplesRichard T Penson
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Gynecol Oncol 93:98-106. 2004..However, P-gp over-expression is a significant prognostic factor, and at the time of disease, relapse is inversely correlated with tumor response to paclitaxel...
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trialWeidong Lu
Leonard P Zakim Center for Integrative Therapies, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Altern Complement Med 15:745-53. 2009..The objective of this study was to investigate the effect of acupuncture administered during myelosuppressive chemotherapy on white blood cell (WBC) count and absolute neutrophil count (ANC) in patients with ovarian cancer...
The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronideRichard T Penson
Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE
Br J Clin Pharmacol 53:347-54. 2002..This circuitous route accounts for the majority of systemically available M6G after oral administration...
Ovarian stromal and germ cell tumorsCarolyn R Koulouris
Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Semin Oncol 36:126-36. 2009..Most patients with germ cell tumors require adjuvant chemotherapy with bleomycin, etoposide, and cisplatin (BEP), as well as careful surveillance. The rarity of these tumors makes basic scientific advances more challenging...
Silence as the speech of careCorrina Lee
Division of Hematology at Massachusetts General Hospital, Boston, USA
J Support Oncol 2:455-6. 2004
Epithelioid angiosarcoma of the uterus: a review of managementAlexander B Olawaiye
Gynecologic Oncology Division, Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Arch Gynecol Obstet 278:401-4. 2008..Uterine epithelioid angiosarcoma is extremely rare. Evidence-based advice regarding optimal management is lacking...
Faith, identity, and leukemia: when blood products are not an optionKristine A Knuti
Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 7:371-80. 2002..Jehovah's Witness beliefs regarding blood products are reviewed. Caregiver roles and responsibilities are discussed in the context of psychosocial, legal, familial, and ethical issues...
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian massRichard T Penson
Cancer Center, Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, USA
N Engl J Med 351:2531-8. 2004
Cone damage in patients receiving high-dose irofulven treatmentMichael S Lee
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44124, USA
Arch Ophthalmol 123:29-34. 2005..To describe the clinical, perimetric, and electroretinographic (ERG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient's retinas...
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapyMory Nouriani
Division of Gynecologic Oncology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 10:2681-6. 2004....
